Inhibiteur de tyrosine,kinase de seconde generation : place en 2012 en premiere ligne

摘要

In France, the only second,generation tyrosine,kinase inhibitor (2GTKIs) available as a first,line treatment is nilotinib. Trials comparing nilotinib with imatinib and dasatinib with imati, nib favour 2GTKIs, which have faster, deeper and earlier molecular responses. However, a reduction in progress is also observed only in a small number of patients. Moreover, survival rates after 3 years are comparable for imatinib and 2GTKIs. For the initial imatinib prescription, it is important to take into consideration the early molecular response (between 3 to 6 months) so treatment modifications for patients considered as non,responders can be made as soon as possible. For prescriptions of 2GTKIs, it is important to take into consideration the comor, bidities of patients and to implement a monitoring programme to detect and prevent emerging side effects.